Pilot Study Suggests New Dosing Considerations for EPI Patients


A study published on March 12, 2019, titled “Clinical validation of an evidence-based method to adjust Pancreatic Enzyme Replacement Therapy through a prospective interventional study in paediatric patients with Cystic Fibrosis” analyzed the relationship between pancreatic enzyme replacement therapy (PERT) dosing, patients’ individual characteristics such as age, gender, and body mass index, as well as patients’ diets. This study evaluated the variability in fat absorption in cystic fibrosis patients after they took a uniform PERT dose while eating a fixed diet for 24 hours. The results of the study indicate that fat absorption was mostly consistent across the study participants, which suggests that an optimal PERT dose for a specific patient may have more to do with the type of food they eat as opposed to their age, gender, weight, and genetic mutations related to cystic fibrosis. This also helps validate an in-development PERT dosing method that can be used to determine the optimal PERT dose for patients. Continue reading.


Comments are closed.